GLP-1 Shock: Lean Mass Vanishes

Businessman with briefcase casts a large muscular shadow on wall — Photo: Shutterstock

Drug makers are racing to pair GLP-1 weight-loss drugs with muscle-preserving meds that promise leaner, stronger results.

Story Snapshot

GLP-1 drugs cut fat fast but also trim lean mass for many patients.
Regeneron’s add-on antibody cut about half the lean-mass loss seen with semaglutide in Phase 2.
Several companies are testing muscle-sparing combos and next-gen incretins.
One developer halted a trial, showing the field is hot but not simple.

Why muscle-preserving add-ons are moving to center stage

Doctors now use glucagon-like peptide-1 drugs such as semaglutide and tirzepatide to drive large fat loss. Trials and reviews show a meaningful share of total weight lost comes from lean mass as well, often around one quarter, even as fat loss dominates. That tradeoff matters for function, aging, and long-term health. It also opens a market for add-on therapies that can protect muscle while patients lose fat, a combination many patients and clinicians want.

Regeneron reported Phase 2 data from its COURAGE trial that backs this strategy. The company said semaglutide’s weight loss included about one-third lean mass, and adding its anti-myostatin antibody trevogrumab, with or without garetosmab, cut about half of that lean-mass loss during treatment. That finding points to a practical win: keep most of the fat loss while sparing more muscle. That balance could reduce frailty risk and help patients keep moving and working.

The pipeline: antibodies, triple agonists, and selective muscle support

Scholar Rock won clearance to start a Phase 2 proof-of-concept obesity trial with apitegromab, which targets the same myostatin pathway that controls muscle growth. Eli Lilly advanced retatrutide, a triple agonist, through Phase 3 after earlier trials showed strong weight loss while researchers continue to track body composition signals. Companies like Rivus are also exploring oral GLP-1 designs that aim to spare muscle in preclinical work, showing how broad the innovation push has become.

Other routes include selective androgen receptor modulators paired with GLP-1 therapy. Published reports describe combinations that sharply reduced lean-mass loss versus GLP-1 alone in clinical settings, suggesting a path to “higher-quality” weight loss when supervised and dosed with care. Reviews still urge caution: dual-energy X-ray absorptiometry “lean mass” is not the same as pure skeletal muscle, and function can hold steady even as lean mass falls modestly.

Signals, setbacks, and what conservative common sense says

Momentum does not guarantee smooth sailing. Eli Lilly ended one clinical trial of a muscle-sparing obesity drug for business reasons, a reminder that cost, strategy, and real-world demand shape the race as much as biology. Conservative common sense says judge these therapies by clear outcomes: strength, mobility, work capacity, independence in older adults, and safety over time. Surrogate scans help, but day-to-day function and lower healthcare burden should be the bar.

For patients already on glucagon-like peptide-1 drugs, clinicians often start with basics that work: resistance exercise and a higher-protein diet, which help preserve muscle during weight loss and support bone health. Add-on drugs may raise the floor further. The emerging picture suggests a “stack”: lifestyle first, GLP-1 for fat loss, then targeted muscle protection when risk is higher or goals are ambitious. That ladder fits both medical prudence and cost discipline.

What to watch next: proof beyond the scan

Phase 3 body-composition and function data will decide which ideas last. Trials that show patients keep more strength, climb stairs faster, and avoid falls will earn trust. Programs that only shift a scan number without better living will fade. Companies that deliver convenient dosing and fair pricing will gain an edge. If these boxes get checked, muscle-preserving meds will not replace glucagon-like peptide-1 drugs; they will ride shotgun and make results sturdier for the long haul.